A sense of the bigger picture: A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use

Summary

This research explored how 15 people with bipolar disorder who used psilocybin mushrooms experienced the effects. Many reported benefits like reduced depression and improved outlook on life, but some experienced negative effects including sleep problems and increased manic episodes. The study identified important factors that influenced outcomes, such as whether people used other drugs simultaneously, whether they used psilocybin alone or with others, and how much sleep they had before use. The researchers concluded that while psilocybin shows promise for bipolar depression, more careful clinical research is needed to ensure safety.

Background

Bipolar disorder affects approximately 2.4% of the global population and is among the leading causes of disability worldwide. Current pharmacological treatments for bipolar depression are inadequate with inconsistent efficacy and significant side effects. Emerging evidence suggests psilocybin is a promising treatment for unipolar depression, yet clinical trials universally exclude individuals with bipolar disorder diagnoses.

Objective

This study aimed to understand subjective impacts of psilocybin use on bipolar disorder symptoms through follow-up qualitative interviews with survey respondents. The research sought to deepen understanding of preliminary survey results and elucidate specific contextual factors associated with adverse reactions in naturalistic settings.

Results

Three major themes emerged: mental health improvements including decreased depression severity, increased emotion processing, new perspectives, and improved sleep; undesired mental health impacts including sleep changes, increased mania severity, hospitalization, and distressing sensory experiences; and contextual factors including polysubstance use and dose, solo versus social experiences, and pre-psilocybin sleep deprivation.

Conclusion

The study demonstrates both benefits and risks of psilocybin use in people with bipolar disorder. Carefully designed clinical trials focused on safety and preliminary efficacy are warranted. Contextual factors such as set and setting appear to significantly influence outcomes.
Scroll to Top